The Pharma Data

SEPTEMBER 28, 2021

In addition, results from Part 1 of Study SRP-9001-102, an ongoing, randomised, double-blind, placebo-controlled clinical test evaluating the security , efficacy, and tolerability of one dose of SRP-9001 in 41 boys with DMD, showed that the study met its primary biological endpoint of change in micro-dystrophin protein expression from baseline.

Clinical Trials 52

Clinical Trials Protein Expression FDA Therapies 52

The Pharma Data

DECEMBER 8, 2020

Silverback’s lead candidate is currently in a Phase I trial in adults with HER2-expressing solid tumors. The fully integrated pharmaceutical company creates value through China’s specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory. SciNeuro Pharmaceuticals . Nuance Pharma .

RNA 52

RNA Protein Expression Therapies Disease 52

The Pharma Data

JANUARY 15, 2021

3 HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumors including breast, gastric, lung and colorectal cancer. Related Articles: Enhertu (fam-trastuzumab deruxtecan-nxki) FDA Approval History. 2,5 In the U.S., About Daiichi Sankyo. Accessed January 2021.

Treatment 52

Treatment Trials Disease Therapies 52

Conversations in Drug Development Trends

MAY 30, 2024

From drugs previously FDA-approved for gallstone diseases, Parkinson’s disease, and even cancer, researchers are working tirelessly to test and establish whether these pharmacotherapies with well-defined safety profiles may have any potential for efficacy in treating ALS.

Treatment 81

Treatment Small Molecule Clinical Trials Therapies 81

The Pharma Data

SEPTEMBER 10, 2020

Until the FDA approval of OCREVUS, there had been no FDA approved treatments for PPMS. About OCREVUS® (ocrelizumab) OCREVUS is the first and only therapy approved for both RMS (including clinically isolated syndrome, RRMS and active, or relapsing, SPMS, in addition to CIS in the U.S.)

Treatment 52

Treatment FDA Approval Disease Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Until the FDA approval of OCREVUS, there had been no FDA approved treatments for PPMS. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved.

Clinical Trials 52

Clinical Trials Trials Disease FDA Approval 52

The Pharma Data

SEPTEMBER 2, 2020

New Phase III data from SAkuraStar and SAkuraSky studies demonstrate reduced severity of relapses with ENSPRYNG (satralizumab), recently FDA-approved as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD).

Clinical Trials 52

Clinical Trials Disease Treatment Therapies 52